FR2535203A1 - Nouvelle composition therapeutique a base d'une association d'un acide amine avec un triterpene et son procede de preparation - Google Patents
Nouvelle composition therapeutique a base d'une association d'un acide amine avec un triterpene et son procede de preparation Download PDFInfo
- Publication number
- FR2535203A1 FR2535203A1 FR8218096A FR8218096A FR2535203A1 FR 2535203 A1 FR2535203 A1 FR 2535203A1 FR 8218096 A FR8218096 A FR 8218096A FR 8218096 A FR8218096 A FR 8218096A FR 2535203 A1 FR2535203 A1 FR 2535203A1
- Authority
- FR
- France
- Prior art keywords
- ursolic acid
- triterpene
- amino acid
- solvent
- leaves
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 14
- 150000001413 amino acids Chemical class 0.000 title claims abstract description 8
- 150000003648 triterpenes Chemical class 0.000 title claims abstract description 8
- 238000000034 method Methods 0.000 title claims description 10
- 230000001225 therapeutic effect Effects 0.000 title claims description 4
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 claims abstract description 22
- 229940096998 ursolic acid Drugs 0.000 claims abstract description 22
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 claims abstract description 22
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229940000635 beta-alanine Drugs 0.000 claims abstract description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 39
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 235000002020 sage Nutrition 0.000 claims description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 239000003208 petroleum Substances 0.000 claims description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 238000000746 purification Methods 0.000 claims description 6
- 240000007164 Salvia officinalis Species 0.000 claims description 5
- 235000002912 Salvia officinalis Nutrition 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 4
- 238000001953 recrystallisation Methods 0.000 claims description 4
- 239000000470 constituent Substances 0.000 claims description 3
- 235000019804 chlorophyll Nutrition 0.000 claims description 2
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 claims description 2
- 239000003797 essential amino acid Substances 0.000 claims description 2
- 235000020776 essential amino acid Nutrition 0.000 claims description 2
- 239000000341 volatile oil Substances 0.000 claims description 2
- 239000001993 wax Substances 0.000 claims description 2
- 229940126601 medicinal product Drugs 0.000 abstract 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 230000037315 hyperhidrosis Effects 0.000 description 8
- 239000002775 capsule Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 238000007873 sieving Methods 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 239000000812 cholinergic antagonist Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- 230000001078 anti-cholinergic effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000002803 maceration Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000005325 percolation Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000003204 tranquilizing agent Substances 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- -1 triterpene acids Chemical class 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- GXWUEMSASMVWKO-GNLHUFSQSA-N (4as,6ar,6as,6br,10s,12ar,14br)-10-[(2s,3r,4s,5s)-4,5-dihydroxy-3-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid Chemical compound O([C@@H]1[C@@H](O)[C@@H](O)CO[C@H]1O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CCC2C1(C)C)C)(C)CC[C@]1(CCC(C[C@@H]14)(C)C)C(O)=O)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GXWUEMSASMVWKO-GNLHUFSQSA-N 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- LCTZPQRFOZKZNK-UHFFFAOYSA-N 4-(diphenylmethylene)-1,1-dimethylpiperidin-1-ium Chemical compound C1C[N+](C)(C)CCC1=C(C=1C=CC=CC=1)C1=CC=CC=C1 LCTZPQRFOZKZNK-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241001106067 Atropa Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000033830 Hot Flashes Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- 206010023644 Lacrimation increased Diseases 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 229960005116 diphemanil Drugs 0.000 description 1
- BREMLQBSKCSNNH-UHFFFAOYSA-M diphemanil methylsulfate Chemical compound COS([O-])(=O)=O.C1C[N+](C)(C)CCC1=C(C=1C=CC=CC=1)C1=CC=CC=C1 BREMLQBSKCSNNH-UHFFFAOYSA-M 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 1
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000004317 lacrimation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960004011 methenamine Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- CTYRPMDGLDAWRQ-UHFFFAOYSA-N phenyl hydrogen sulfate Chemical compound OS(=O)(=O)OC1=CC=CC=C1 CTYRPMDGLDAWRQ-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000003236 psychic effect Effects 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 150000003675 ursolic acids Chemical class 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8218096A FR2535203A1 (fr) | 1982-10-28 | 1982-10-28 | Nouvelle composition therapeutique a base d'une association d'un acide amine avec un triterpene et son procede de preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8218096A FR2535203A1 (fr) | 1982-10-28 | 1982-10-28 | Nouvelle composition therapeutique a base d'une association d'un acide amine avec un triterpene et son procede de preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2535203A1 true FR2535203A1 (fr) | 1984-05-04 |
| FR2535203B1 FR2535203B1 (enrdf_load_stackoverflow) | 1985-04-19 |
Family
ID=9278697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8218096A Granted FR2535203A1 (fr) | 1982-10-28 | 1982-10-28 | Nouvelle composition therapeutique a base d'une association d'un acide amine avec un triterpene et son procede de preparation |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR2535203A1 (enrdf_load_stackoverflow) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1002521A1 (de) * | 1998-11-19 | 2000-05-24 | Heilmittelbetrieb Isernhagen GmbH | Verwendung von Salbeiextrakten als Deodorantien |
| EP3777824A4 (en) * | 2018-03-28 | 2022-03-09 | Mandom Corporation | ANTIPERSPIRANT |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2152365A1 (en) * | 1971-09-08 | 1973-04-27 | Serdex | Triterpenic acid compsns - for modification of protein synthesis esp in collagen diseases |
-
1982
- 1982-10-28 FR FR8218096A patent/FR2535203A1/fr active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2152365A1 (en) * | 1971-09-08 | 1973-04-27 | Serdex | Triterpenic acid compsns - for modification of protein synthesis esp in collagen diseases |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1002521A1 (de) * | 1998-11-19 | 2000-05-24 | Heilmittelbetrieb Isernhagen GmbH | Verwendung von Salbeiextrakten als Deodorantien |
| US6139825A (en) * | 1998-11-19 | 2000-10-31 | Heilmittelbetreib Isernhagen Gmbh | Use of extracts from sage for producing a deodorizing preparation |
| EP3777824A4 (en) * | 2018-03-28 | 2022-03-09 | Mandom Corporation | ANTIPERSPIRANT |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2535203B1 (enrdf_load_stackoverflow) | 1985-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102212093B (zh) | 黄酮苷类化合物及其制备方法和用途 | |
| US10265345B2 (en) | Use of extracts from rabbit skin inflamed by vaccinia virus for the manufacture of a medicament for the treatment of acute cerebrovascular disease | |
| US7579023B2 (en) | Method of preparation and composition of a water soluble extract of the bioactive component of the plant species Uncaria for enhancing immune, anti-inflammatory, anti-tumor and DNA repair processes of warm blooded animals | |
| BE895724A (fr) | Nouvelle utilisation therapeutique de la dihydrocyclosporine d | |
| CA1170572A (fr) | Composition pharmaceutique a usage topique a base d'un extrait total d'hedysarum fructescens willd | |
| JP2022510743A (ja) | 丹参（Ｓａｌｖｉａ ｍｉｌｔｉｏｒｒｈｉｚａ Ｂｕｎｇｅ）抽出物を有効成分として含む前立腺肥大症又は脱毛症の治療又は予防用組成物 | |
| EP1014927B1 (fr) | Utilisation des shogaols et des gingerols pour la preparation de compositions deodorantes | |
| CA2283122A1 (fr) | Compositions d'extraits de plantes, leur procede de preparation, et compositions pharmaceutiques les renfermant | |
| KR20110121246A (ko) | 비만개선 다이어트용 웰빙 한방식품 및 그 제조방법 | |
| JP2018502119A (ja) | 男性更年期症状の予防または改善用組成物 | |
| FR2535203A1 (fr) | Nouvelle composition therapeutique a base d'une association d'un acide amine avec un triterpene et son procede de preparation | |
| JP2018168144A (ja) | リパーゼ阻害剤、及びその利用 | |
| KR20110021844A (ko) | 매실나무 추출물의 조성물 제조에서의 응용 | |
| BRPI0106382B1 (pt) | Process for obtaining decocts from vitis labrusca and vitis vinifera casts, process for obtaining the hydro-alcoholic extract, process for obtaining the hydro-alcoholic extract-ethyl acetate and pharmaceutical compositions | |
| JP2005001998A (ja) | 血圧降下剤及びその製造方法、並びにプロポリス組成物及び食品製剤 | |
| FR3064180A1 (fr) | Formulations comprenant des actifs issus de la plante murraya koenigii | |
| JP7663359B2 (ja) | 変性エラスチンの分解低下の抑制剤、正常なエラスチン線維の維持剤、エラスチン－エラフィン複合体形成抑制剤及びエラスチン－エラフィン複合体形成抑制作用を有する物質のスクリーニング方法 | |
| WO2006123464A1 (ja) | 膵臓機能改善のための医薬又は飲食品 | |
| EP3890729A1 (en) | Bioactive phytochemicals in zizyphus and guarana | |
| Devi et al. | Synthesis of Different Dipeptides From 4-Hydroxy Isoleucine and Evaluation of Their Anti-Diabetic Activity | |
| WO2013012302A2 (fr) | Elaboration d'un sirop anti-inflammatoire/anti-œdemateux naturel a base d'extraits aqueux de plantes originaires du sud-est du maroc | |
| KR20190111726A (ko) | 천연 혼합 추출물을 포함하는 비만 예방 또는 치료용 조성물 | |
| RU2319496C2 (ru) | Способ получения гепатопротективного средства, обладающего антиоксидантной активностью | |
| US20220273745A1 (en) | Medicinal composition of amaranth origin for cardiovascular treatment | |
| Rao et al. | Hypolipidemic effect of dichloromethane as well as methanolic fruit and leaf extract of Ethiopian alligator pear (persea americana mill.) on tyloxapol-induced hyperlipidemic experimental rat |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |